CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 475 enrolled
Drug / intervention
Terconazole +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02308007
NCT02308007Phase 3Completed
CompareCT.gov

Solubilized Metronidazole And/oR Terconazole Gels Intra-Vaginal Efficacy and Safety

Curatek Pharmaceuticals, LLC·interventional·Posted Dec 4, 2014·Updated Aug 4, 2020

In Brief

A Phase 3 clinical trial evaluating Terconazole, Metronidazole, and 1 other intervention for Vaginal Infection. Completed, enrolled 475 participants across 51 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of terconazole/metronidazole gel in the treatment of vaginal infections

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaginal Infection
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 4, 2014
Enrollment StartJun 1, 2015
Primary CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 11.6 years ago

Interventions

Terconazoledrug

Metronidazoledrug

Terconazole/metronidazoledrug